Pharma BD Deal Intelligence
Aged as a financial-engineering win, not an operating win: Nycomed flipped the Altana-enlarged business to Takeda for ~2x five years later, but the acquired pantoprazole franchise collapsed on patent cliff and the flagship pipeline asset (Daxas) stumbled badly in the US.
Full analysis, sources & comparables →Observers offered mixed perspectives; some praised the price and geographic expansion while others questioned Nycomed's relatively weak product pipeline and…
FDA approval of Daliresp (roflumilast) validated the 2006 deal thesis — Nycomed shepherded Altana's signature pipeline asset through to approval as the first…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
EUR 4.5B; pulmonary (Daxas), GI (Pantoprazole)
Aged as a financial-engineering win, not an operating win: Nycomed flipped the Altana-enlarged business to Takeda for ~2x five years later, but the acquired pantoprazole franchise collapsed on patent cliff and the flagship pipeline asset (Daxas) stumbled badly in the US.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nycomed / Altana Pharma AG (this deal) | 2006 | $5.7B | 59 |
| Nycomed / Altana Pharma AG | 2007 | $4.5B | 58 |
| Nycomed / Bradley Pharmaceuticals | 2007 | $346M | 48 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
← Browse all deals · How we score deals
More: 2006 deals · Nycomed deals